Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Effectiveness of Cyclosporine in a 10-year-old Girl with C3 Glomerulopathy

  • Jang, Kyung Mi (Department of Pediatrics, Yeungnam University College of Medicine) ;
  • Park, Yong Hoon (Department of Pediatrics, Yeungnam University College of Medicine)
  • Received : 2017.08.07
  • Accepted : 2017.09.18
  • Published : 2017.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

C3 glomerulopathy (C3G) is a recently defined pathological entity characterized by C3 accumulation with absent or scant immunoglobulin deposition, leading to variable glomerular inflammation. The clinical presentation of patients with C3G is highly variable, as they may present with symptoms ranging from microscopic or mild proteinuria to full-blown nephrotic syndrome, with or without renal impairment. However, there is no consensus recommendation for specific treatment in children with C3G. Recently, new therapies have been suggested to target complement pathways, owing to an improvement in the understanding of the pathogenesis of C3G. C3G complement blockade with eculizumab, a monoclonal antibody targeted against complement C5, inhibits activation of the alternative complement pathway. We could not use eculizumab owing to its high price; thus, we administered oral prednisolone and mycophenolate mofetil (MMF). MMF was replaced with cyclosporine because proteinuria persisted, with a consistently low serum C3 level; we tapered off the prednisolone because of a Cushingoid appearance and amenorrhea. Thereafter, proteinuria improved, and the serum C3 level returned to normal. Thus, we report the effectiveness of cyclosporine in a patient with C3G and an inadequate response to prednisolone and MMF, who was detected via school urinary screening.

Keywords

References

  1. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012;82:465-73. https://doi.org/10.1038/ki.2012.212
  2. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: consensus report. Kidney Int 2013;84:1079-89. https://doi.org/10.1038/ki.2013.377
  3. Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012;8:634-42.
  4. Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007;18:2447-56. https://doi.org/10.1681/ASN.2007030356
  5. Nester CM, Smith RJ. Diagnosis and treatment of C3 glomerulopathy. Clin Nephrol 2013;80:395-403. https://doi.org/10.5414/CN108057
  6. Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014;9:46-53. https://doi.org/10.2215/CJN.04700513
  7. Fakhouri F, Fremeaux-Bacchi V, Noel LH, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010;6:494-9. https://doi.org/10.1038/nrneph.2010.85
  8. Master Sankar Raj V, Gordillo R, Chand DH. Overview of C3 Glomerulopathy. Front Pediatr 2016;4.
  9. Barbour TD, Pickering MC, Cook HT. Recent insights into C3 glomerulopathy. Nephrol Dial Transplant 2013;28:1685-93. https://doi.org/10.1093/ndt/gfs430
  10. Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983;74:175-92. https://doi.org/10.1016/0002-9343(83)90606-X
  11. Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 2006;69:504-11. https://doi.org/10.1038/sj.ki.5000084
  12. Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82:454-64. https://doi.org/10.1038/ki.2012.63
  13. Daina E, Noris M, Remuzzi G. Eculizumab in a Patient with Dense-Deposit Disease. N Engl J Med 2012;366:1161-3. https://doi.org/10.1056/NEJMc1112273
  14. Rabasco C, Cavero T, Roman E, Rojas-Rivera J, Olea T, Espinosa M, et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88:1153-60. https://doi.org/10.1038/ki.2015.227
  15. Lioufas N, Finlay M, Barbour T. Durable remission of C3 glomerulonephritis with mycophenolate mofetil. Nephrology (Carlton) 2017;22 Suppl 1:36-9.
  16. Goodship THJ, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51. https://doi.org/10.1016/j.kint.2016.10.005
  17. Bagheri N, Nemati E, Rahbar K, Nobakht A, Einollahi B, Taheri S. Cyclosporine in the treatment of membranoproliferative glomerulonephritis. Arch Iran Med 2008;11:26-9.
  18. Ruseva MM, Peng T, Lasaro MA, Bouchard K, Liu-Chen S, Sun F, et al. Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy. J Am Soc Nephrol 2016;27:405-16. https://doi.org/10.1681/ASN.2014121195
  19. Lebreton C, Bacchetta J, Dijoud F, Bessenay L, Fremeaux-Bacchi V, Sellier-Leclerc AL. C3 glomerulopathy and eculizumab: a report on four paediatric cases. Pediatr Nephrol 2017;32:1023-8. https://doi.org/10.1007/s00467-017-3619-2
  20. Kiyomasu T, Shibata M, Kurosu H, Shiraishi K, Hashimoto H, Hayashidera T, et al. Cyclosporin A Treatment for Membranoproliferative Glomerulonephritis Type II. Nephron 2002;91:509-11. https://doi.org/10.1159/000064298
  21. Lee S-J, Moon J-H, Kang M-S, Song M-S, Chung W-Y. A Case of Membranoproliferative Glomerulonephritis Type II(Dense-Deposit Disease). Child Kidney Dis 2003;7:204-10.
  22. Singh A, Tejani C, Tejani A. One-center experience with cyclosporine in refractory nephrotic syndrome in children. Pediatr Nephrol 1999;13:26-32. https://doi.org/10.1007/s004670050557